Compare PROK & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROK | NAKA |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 347.4M |
| IPO Year | N/A | 2024 |
| Metric | PROK | NAKA |
|---|---|---|
| Price | $2.26 | $0.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $6.25 | $4.50 |
| AVG Volume (30 Days) | 1.4M | ★ 15.8M |
| Earning Date | 11-10-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $744,000.00 | ★ $1,980,278.00 |
| Revenue This Year | $918.66 | N/A |
| Revenue Next Year | N/A | $2,755.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $0.43 |
| 52 Week High | $7.13 | $34.77 |
| Indicator | PROK | NAKA |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 30.74 |
| Support Level | $2.04 | $0.45 |
| Resistance Level | $2.25 | $0.58 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 26.19 | 17.57 |
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.